Soluble interleukin-2 receptor (sIL-2R) and tumor necrosis factor plasma levels in renal allograft recipients.
Noronha
I L
IL
Department of Transplantation Immunology, University of Heidelberg, FRG.
Daniel
V
V
Rambausek
M
M
Waldherr
R
R
Opelz
G
G
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D003524:Cyclosporins / Q000009:adverse effects; D006084:Graft Rejection; D006801:Humans; D007165:Immunosuppression Therapy; D016030:Kidney Transplantation / Q000276:immunology / Q000473:pathology / Q000502:physiology*; D016853:Muromonab-CD3; D015375:Receptors, Interleukin-2 / Q000032:analysis*; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis*; D014777:Virus Diseases / Q000097:blood / Q000276:immunology
D000911:Antibodies, Monoclonal; D003524:Cyclosporins; D016853:Muromonab-CD3; D015375:Receptors, Interleukin-2; D014409:Tumor Necrosis Factor-alpha